SCIPHER MEDICINE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2015-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
2
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Scipher Medicine
- Target Recruit Count
- 1100
- Registration Number
- NCT06390709
- Locations
- 🇺🇸
Medvin Clinical Research//Amicus Arthritis, Whittier, California, United States
A Clinical Utility Study of PrismRA for Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Scipher Medicine
- Target Recruit Count
- 613
- Registration Number
- NCT05161234
- Locations
- 🇺🇸
Arizona Arthritis, Chandler, Arizona, United States
🇺🇸Medvin Clinical Research//Covina Arthritis Clinic, Covina, California, United States
🇺🇸Southland Arthritis, Hemet, California, United States
News
Scipher Medicine and Kythera Labs Form Strategic Partnership to Advance Precision Medicine in Rheumatology
Scipher Medicine and Kythera Labs have partnered to integrate clinical and genomic data from Scipher's PrismRA® Test with Kythera's multi-source EHR and claims data, achieving a 98% match rate while maintaining privacy protection.
Scipher Medicine Expands Precision Medicine Partnerships to Transform Rheumatoid Arthritis Treatment
• Scipher Medicine has formed strategic partnerships with OMNY Health and Atropos Health to integrate its PrismRA test data into larger healthcare networks, creating comprehensive clinico-transcriptomic datasets for autoimmune disease research. • The OMNY Health collaboration connects Scipher's genomic insights from over 40,000 rheumatoid arthritis patients with OMNY's EHR network covering 80 million patients, enabling more targeted therapy development and improved patient outcomes. • Through the Atropos Health partnership, Scipher's precision medicine diagnostic data will enhance the Atropos Evidence Network, allowing clinicians to generate real-world evidence in minutes for personalized rheumatoid arthritis treatment decisions.